Sivik Global Healthcare LLC Acquires New Stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Sivik Global Healthcare LLC purchased a new position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 10,000 shares of the biotechnology company’s stock, valued at approximately $1,216,000.

Several other hedge funds have also recently added to or reduced their stakes in the business. The Manufacturers Life Insurance Company boosted its stake in Sarepta Therapeutics by 121.7% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 89,525 shares of the biotechnology company’s stock worth $14,145,000 after purchasing an additional 49,137 shares during the period. Creative Planning boosted its stake in Sarepta Therapeutics by 11.7% in the 2nd quarter. Creative Planning now owns 7,937 shares of the biotechnology company’s stock worth $1,254,000 after purchasing an additional 829 shares during the period. EP Wealth Advisors LLC boosted its stake in Sarepta Therapeutics by 2.1% in the 2nd quarter. EP Wealth Advisors LLC now owns 4,899 shares of the biotechnology company’s stock worth $774,000 after purchasing an additional 103 shares during the period. Truist Financial Corp boosted its stake in Sarepta Therapeutics by 86.5% in the 2nd quarter. Truist Financial Corp now owns 4,003 shares of the biotechnology company’s stock worth $632,000 after purchasing an additional 1,857 shares during the period. Finally, Cetera Investment Advisers boosted its stake in shares of Sarepta Therapeutics by 8.5% during the 2nd quarter. Cetera Investment Advisers now owns 13,013 shares of the biotechnology company’s stock valued at $2,056,000 after buying an additional 1,022 shares during the period. Institutional investors and hedge funds own 86.68% of the company’s stock.

Insiders Place Their Bets

In other Sarepta Therapeutics news, Director Kathryn Jean Boor sold 1,636 shares of Sarepta Therapeutics stock in a transaction on Thursday, December 5th. The shares were sold at an average price of $125.55, for a total value of $205,399.80. Following the sale, the director now directly owns 5,880 shares in the company, valued at approximately $738,234. The trade was a 21.77 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of Sarepta Therapeutics stock in a transaction on Thursday, December 12th. The shares were sold at an average price of $124.84, for a total transaction of $1,310,820.00. Following the completion of the sale, the director now owns 22,840 shares in the company, valued at $2,851,345.60. The trade was a 31.49 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 7.70% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have issued reports on SRPT. StockNews.com lowered shares of Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, November 20th. Evercore ISI decreased their target price on shares of Sarepta Therapeutics from $179.00 to $170.00 and set an “outperform” rating for the company in a research note on Thursday, November 7th. Raymond James reissued an “outperform” rating and set a $150.00 target price on shares of Sarepta Therapeutics in a research note on Thursday, October 10th. Robert W. Baird decreased their price objective on shares of Sarepta Therapeutics from $200.00 to $193.00 and set an “outperform” rating for the company in a report on Thursday, November 7th. Finally, Guggenheim upped their price objective on shares of Sarepta Therapeutics from $148.00 to $150.00 and gave the stock a “buy” rating in a report on Thursday, November 7th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, nineteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $178.71.

Sarepta Therapeutics Trading Down 2.0 %

SRPT opened at $115.18 on Thursday. The firm’s fifty day moving average is $122.73 and its two-hundred day moving average is $127.59. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84. The firm has a market cap of $11.00 billion, a PE ratio of 92.96 and a beta of 0.77. Sarepta Therapeutics, Inc. has a twelve month low of $102.15 and a twelve month high of $173.25.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.